Annovis Bio prices $21.0 million public offering of shares and warrants
Annovis Bio agreed on November 5, 2026 to sell 19,000,000 shares of common stock (or pre-funded warrants in lieu of shares) with accompanying warrants, with expected gross proceeds of approximately $21.0 million before underwriting discounts and expenses. The offering adds shares and warrants that could dilute existing shareholders, while the company plans to use the proceeds for clinical development of buntanetap and working capital.
Key points
- Offering of 19,000,000 shares plus pre-funded warrants for up to 2,000,000 shares, with accompanying warrants for up to 21,000,000 shares, priced at $1.00 per share and accompanying warrant
- Accompanying warrants are exercisable at $1.00 per share and expire five years after issuance
- One of the company's directors is buying 5,000,000 shares and accompanying warrants for $5,000,000
- Offering is expected to close on or about November 6, 2026, with Canaccord Genuity LLC as underwriter
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.